Advertisement
Advertisement

Abbott could restart infant formula production at Michigan plant in two weeks

By:
Reuters
Updated: May 11, 2022, 19:06 GMT+00:00

(Reuters) - Abbott Laboratories said on Wednesday it could restart production of infant formula at its troubled Michigan facility within two weeks.

Abbott Laboratories logo is displayed on a screen at the NYSE in New York

(Reuters) -Abbott Laboratories said on Wednesday it could restart production of infant formula at its troubled Michigan facility within two weeks.

The company in February recalled some baby formulas, including certain Similac products, made at the plant in Sturgis after complaints about bacterial infections in infants who had consumed the products.

Abbott will restart production of EleCare, Alimentum and metabolic formulas first, followed by Similac and other brands, after receiving the go-ahead from the U.S. Food & Drug Administration (FDA).

Once production is resumed, it will take six to eight weeks before the product returns to shelves.

Abbott is the leading supplier of milk formula in the United States and the recall has driven a shortage across the country, forcing many leading retailers to limit purchases.

The FDA has said it is working with manufacturers to alleviate supply issues and that several companies are at or over capacity.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli and Devika Syamnath)

About the Author

Reuterscontributor

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products:

Advertisement